SCHEMBL22979159

SCHEMBL22979159

O=C1NCCCC[C@H]1Nc1nc2ccccc2c2nc(-c3ccc(F)cc3OC(F)(F)F)nn12

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
MAPT P10636 2/20 0.35
MGLL Q99685 1/20 0.35
C1R P00736 1/20 0.35
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
PLAT P00750 4/20 0.33
ACP1 P24666 1/20 0.33
TACR2 P21452 2/20 0.33
TACR1 P25103 2/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRIA1 P42261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29648679 1.00 MKNK1 (0.36) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL29648649 0.95 MAPT (0.36) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL29648841 0.95 MAPT (0.36) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL22981140 0.95 MAPT (0.36) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL22979040 0.95 MAPT (0.36) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL22987931 0.93 MKNK1 (0.39) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL22979222 0.93 MKNK1 (0.39) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL29648829 0.93 MKNK1 (0.39) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL29648695 0.93 MKNK1 (0.39) MKNK1MKNK2DDB1CRBNMAPT
SCHEMBL22988023 0.92 MKNK1 (0.38) MKNK1MKNK2DDB1CRBNMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US claimed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP claimed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO claimed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 MKNK1 2220/4885MKNK2 2103/4885DDB1 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.